Create a free Feed Strategy account to continue reading

Novozymes, Chr. Hansen merger completed

The combination of Novozymes and Chr. Hansen is successfully completed, creating Novonesis, a global biosolutions partner.

Merger Acquisition 2
Maksim Labkouski | Bigstock.com

The proposed combination of the legacy companies Novozymes and Chr. Hansen has been successfully completed, establishing the company Novonesis. Novonesis is a biosolutions partner for better business, healthier lives and a healthier planet. The combined company brings together 10,000 people worldwide and an expertise that spans more than 30 different industries. Novonesis is already assisting companies around the world in meeting both business needs and the needs of the planet.

On December 12, 2022, Novozymes and Chr. Hansen entered into an agreement to create a leading global biosolutions partner through a statutory merger of the two companies. All regulatory approvals and registrations are now in place and the proposed combination is successfully completed after the final registration with the Danish Business Authority today.

“We have successfully combined Novozymes and Chr. Hansen and, today, we come together as one leading global biosolutions partner,” said Ester Baiget, president and CEO of Novonesis. “Novonesis combines our joint strengths and the wonders of biology, and we are set to lead a new era of biosolutions. We will innovate and develop transformative biosolutions that improve the way we all produce, consume and live. And we have gathered the brightest minds and, together with my 10,000 colleagues, we will unlock the limitless potential of biosolutions.”